A randomized comparison of trapidil (triazolopyrimidine), a platelet‐derived growth factor antagonist, versus aspirin in prevention of angiographic restenosis after coronary artery Palmaz‐Schatz stent implantation
A randomized comparison of trapidil (triazolopyrimidine), a platelet‐derived growth factor antagonist, versus aspirin in prevention of angiographic restenosis after coronary artery Palmaz‐Schatz stent implantation
复制标题
血小板衍生生长因子拮抗剂曲匹地尔（三唑并嘧啶）与阿司匹林预防冠状动脉 Palmaz-Schatz 支架植入后血管造影再狭窄的随机比较
DOI：
--
复制
发表时间：
1999
影响因子：
2.3
通讯作者：
G. Giuffrida
中科院分区：
文献类型：
--
作者：
A. Galassi;C. Tamburino;A. Nicosia;G. Russo;R. Grassi;A. Monaco;G. Giuffrida
该研究的目的是评估trapidil在冠状动脉支架置入中的安全性，并评估其减少血管造影支架内再狭窄的疗效。118名接受Palmaz - Schatz支架植入的患者被随机分配接受抗血小板治疗，第一个月使用阿司匹林（325 mg/d）或trapidil （400 mg/d）联合噻氯匹定（500 mg）。在入组时，两组在临床、血管造影和手术特征方面具有可比性。在6个月的血管造影随访中，阿司匹林组的52个病变中有15个（28.8%）发生了50%的再狭窄，而trapidil组的47个病变中有14个（29.8%）发生了50%的再狭窄（P =无统计学意义，NS）。在6个月的临床随访中，两组在不良事件发生率（2.0%对2.1%,P = NS）、药物副作用发生率（4.0%对4.2%,P = NS）和外周血管并发症发生率（4.0%对4.2%,P = NS）方面均无差异。总之，与阿司匹林相比，用trapidil治疗似乎与支架再狭窄和不良心脏事件的发生率相似，可能是冠状动脉支架置入中替代阿司匹林的有价值的选择。Cardiovasc。[j] .科学通报，1999。©1999 Wiley‐Liss, Inc。
The aim of the study is to assess the safety of trapidil in the setting of coronary stenting and to evaluate its efficacy in reducing angiographic in‐stent restenosis. One hundred eighteen patients undergoing Palmaz‐Schatz stent implantation were randomly assigned to receive antiplatelet therapy using either aspirin (325 mg/d) or trapidil (400 mg/d), in combination with ticlopidine (500 mg) for the first month. At entry, both groups were comparable with regard to clinical, angiographic, and procedural characteristics. At 6‐month angiographic follow‐up, >50% restenosis occurred in 15 of 52 lesions (28.8%) of the aspirin group and in 14 of 47 lesions (29.8%) of the trapidil group (P = not significant, NS). At 6‐month clinical follow‐up, there was no difference in the two groups in the rate of adverse events (2.0% vs. 2.1%, P = NS), medication side effects (4.0% vs. 4.2%, P = NS), and peripheral vascular complications (4.0% vs. 4.2%, P = NS). In conclusion, treatment with trapidil seems to be associated with a similar incidence of stent restenosis and adverse cardiac events as compared to aspirin and could be a valuable alternative to aspirin in the setting of coronary stenting.Cathet. Cardiovasc. Intervent. 46:162–168, 1999. © 1999 Wiley‐Liss, Inc.
登录
查看更多内容
影响因子：
158.5
作者：
LIBBY, P;WARNER, SJC;BIRINYI, LK
通讯作者：
BIRINYI, LK
影响因子：
37.8
作者：
COLOMBO, A;HALL, P;TOBIS, JM
通讯作者：
TOBIS, JM
影响因子：
37.8
作者：
ROGERS, C;EDELMAN, ER
通讯作者：
EDELMAN, ER
影响因子：
37.8
作者：
Detre,KM;HolmesJr,DR;Holubkov,R;Cowley,MJ;Bourassa,MG;Faxon,DP;Dorros,GR;Bentivoglio,LG;Kent,KM;Myler,RK
通讯作者：
Myler,RK